ReNeuron Group PLC on Wednesday reported a slight narrowing in interim loss as costs decreased, as it highlighted its focus on its exosome delivery platform.

The Brigdend, Wales-based stem cell and exosomes technology company said in the six months to September 30, pretax loss narrowed 15% to £3.2 million from £3.8 million a year prior. Revenue declined to £157,000 from £438,000.

Research and development costs decreased 27% to £2.2 million from £3.0 million, while general and administrative costs were 26% lower, at £1.3 million versus £1.7 million.

Looking ahead, the company said its outlook remained positive as it focused on further developing and verifying its CustomEX exosome delivery platform, and conclude validating industry partnerships.

Exosomes are extracellular vesicles generated by all cells. They care proteins, lipids, nucleic acids and metabolites.

ReNeuron Group shares were 2.1% lower at 5.24 pence each on Wednesday afternoon in London.

Copyright 2023 Alliance News Ltd. All Rights Reserved.